---
title: "Amarin Corporation plc (AMRN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AMRN.US.md"
symbol: "AMRN.US"
name: "Amarin Corporation plc"
industry: "Biotechnology"
datetime: "2026-03-14T06:52:41.737Z"
locales:
  - [en](https://longbridge.com/en/quote/AMRN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AMRN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AMRN.US.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/AMRN.US.md) | [繁體中文](https://longbridge.com/zh-HK/quote/AMRN.US.md)


# Amarin Corporation plc (AMRN.US)

## Company Overview

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.amarincorp.com](https://www.amarincorp.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-03-14T04:30:15.000Z

**Overall: D (0.60)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 252 / 404 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -6.55% |  |
| Net Profit YoY | 52.79% |  |
| P/B Ratio | 0.69 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 319132700.38 |  |
| Revenue | 213646000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -8.21% | D |
| Profit Margin | -18.16% | D |
| Gross Margin | 56.57% | B |
| Revenue YoY | -6.55% | D |
| Net Profit YoY | 52.79% | B |
| Total Assets YoY | -2.13% | D |
| Net Assets YoY | -5.53% | D |
| Cash Flow Margin | -550.66% | E |
| OCF YoY | -6.55% | D |
| Turnover | 0.32 | D |
| Gearing Ratio | 31.53% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Amarin Corporation plc",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-6.55%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "52.79%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.69",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "319132700.38",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "213646000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-8.21%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-18.16%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "56.57%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-6.55%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "52.79%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-2.13%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-5.53%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-550.66%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "-6.55%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.32",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "31.53%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -8.23 | 438/404 | - | - | - |
| PB | 0.69 | 57/404 | 0.73 | 0.67 | 0.50 |
| PS (TTM) | 1.49 | 37/404 | 1.51 | 1.41 | 1.10 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Stoke Therapeutics (STOK.US) | A | A | B | A | B | A |
| 03 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 04 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-06T05:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Hold | 1 | 50% |
| Sell | 1 | 50% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 15.34 |
| Highest Target | 12.00 |
| Lowest Target | 12.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/AMRN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/AMRN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/AMRN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/AMRN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**